CDTX
Price
$21.48
Change
-$0.42 (-1.92%)
Updated
Apr 24, 04:59 PM (EDT)
Capitalization
240.76M
REPL
Price
$9.05
Change
+$0.22 (+2.49%)
Updated
Apr 24, 04:59 PM (EDT)
Capitalization
680.04M
21 days until earnings call
Ad is loading...

CDTX vs REPL

Header iconCDTX vs REPL Comparison
Open Charts CDTX vs REPLBanner chart's image
Cidara Therapeutics
Price$21.48
Change-$0.42 (-1.92%)
Volume$433
Capitalization240.76M
Replimune Group
Price$9.05
Change+$0.22 (+2.49%)
Volume$16.77K
Capitalization680.04M
CDTX vs REPL Comparison Chart
Loading...
CDTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
REPL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CDTX vs. REPL commentary
Apr 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CDTX is a Hold and REPL is a Buy.

Ad is loading...
COMPARISON
Comparison
Apr 24, 2025
Stock price -- (CDTX: $21.88 vs. REPL: $8.83)
Brand notoriety: CDTX and REPL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CDTX: 97% vs. REPL: 87%
Market capitalization -- CDTX: $240.76M vs. REPL: $680.04M
CDTX [@Biotechnology] is valued at $240.76M. REPL’s [@Biotechnology] market capitalization is $680.04M. The market cap for tickers in the [@Biotechnology] industry ranges from $266.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.09B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CDTX’s FA Score shows that 0 FA rating(s) are green whileREPL’s FA Score has 1 green FA rating(s).

  • CDTX’s FA Score: 0 green, 5 red.
  • REPL’s FA Score: 1 green, 4 red.
According to our system of comparison, both CDTX and REPL are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CDTX’s TA Score shows that 5 TA indicator(s) are bullish while REPL’s TA Score has 5 bullish TA indicator(s).

  • CDTX’s TA Score: 5 bullish, 5 bearish.
  • REPL’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, REPL is a better buy in the short-term than CDTX.

Price Growth

CDTX (@Biotechnology) experienced а +14.05% price change this week, while REPL (@Biotechnology) price change was +15.73% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.94%. For the same industry, the average monthly price growth was -5.37%, and the average quarterly price growth was -12.15%.

Reported Earning Dates

CDTX is expected to report earnings on Aug 13, 2024.

REPL is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+7.94% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
REPL($680M) has a higher market cap than CDTX($241M). CDTX YTD gains are higher at: -18.620 vs. REPL (-27.085). CDTX has higher annual earnings (EBITDA): -175.87M vs. REPL (-216.51M). REPL has more cash in the bank: 537M vs. CDTX (190M). CDTX has less debt than REPL: CDTX (3.58M) vs REPL (76M). CDTX has higher revenues than REPL: CDTX (1.28M) vs REPL (0).
CDTXREPLCDTX / REPL
Capitalization241M680M35%
EBITDA-175.87M-216.51M81%
Gain YTD-18.620-27.08569%
P/E RatioN/AN/A-
Revenue1.28M0-
Total Cash190M537M35%
Total Debt3.58M76M5%
FUNDAMENTALS RATINGS
CDTX vs REPL: Fundamental Ratings
CDTX
REPL
OUTLOOK RATING
1..100
2115
VALUATION
overvalued / fair valued / undervalued
1..100
51
Fair valued
27
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9895
PRICE GROWTH RATING
1..100
3764
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a41

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

REPL's Valuation (27) in the Biotechnology industry is in the same range as CDTX (51). This means that REPL’s stock grew similarly to CDTX’s over the last 12 months.

REPL's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as CDTX (100). This means that REPL’s stock grew similarly to CDTX’s over the last 12 months.

REPL's SMR Rating (95) in the Biotechnology industry is in the same range as CDTX (98). This means that REPL’s stock grew similarly to CDTX’s over the last 12 months.

CDTX's Price Growth Rating (37) in the Biotechnology industry is in the same range as REPL (64). This means that CDTX’s stock grew similarly to REPL’s over the last 12 months.

CDTX's P/E Growth Rating (100) in the Biotechnology industry is in the same range as REPL (100). This means that CDTX’s stock grew similarly to REPL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CDTXREPL
RSI
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
77%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
84%
MACD
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
85%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend 3 days ago
85%
Bullish Trend 4 days ago
78%
Declines
ODDS (%)
Bearish Trend 22 days ago
90%
Bearish Trend 21 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
74%
Aroon
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
83%
View a ticker or compare two or three
Ad is loading...
CDTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
REPL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FCPIX32.67N/A
N/A
Fidelity Advisor Intl Cap App I
WPSGX48.57N/A
N/A
AB Concentrated Growth Advisor
PSBPX24.21N/A
N/A
Principal SmallCap R5
STPAX17.75N/A
N/A
Saratoga Technology & Comm A
NWHLX10.11N/A
N/A
Nationwide Bailard Intl Eqs M

CDTX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CDTX has been closely correlated with BPTSY. These tickers have moved in lockstep 92% of the time. This A.I.-generated data suggests there is a high statistical probability that if CDTX jumps, then BPTSY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CDTX
1D Price
Change %
CDTX100%
-0.48%
BPTSY - CDTX
92%
Closely correlated
N/A
IVVD - CDTX
36%
Loosely correlated
+4.61%
CPRX - CDTX
35%
Loosely correlated
+2.30%
REPL - CDTX
34%
Loosely correlated
+1.38%
CABA - CDTX
33%
Poorly correlated
+4.69%
More

REPL and

Correlation & Price change

A.I.dvisor indicates that over the last year, REPL has been loosely correlated with ELVAF. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if REPL jumps, then ELVAF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To REPL
1D Price
Change %
REPL100%
+1.38%
ELVAF - REPL
60%
Loosely correlated
N/A
RCKT - REPL
44%
Loosely correlated
+2.44%
AXON - REPL
41%
Loosely correlated
+3.82%
ORMP - REPL
39%
Loosely correlated
+0.66%
KYMR - REPL
39%
Loosely correlated
+6.56%
More